The NF-KB pathway and endocrine therapy resistance in breast cancer in: Endocrine-Related Cancer Volume 26 Issue 6 (2019)
A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling.,Cell Chemical Biology - X-MOL
Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer
The role of estrogen receptor beta in breast cancer | Biomarker Research | Full Text
Frontiers | Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
Potentiation of ICI182,780 (Fulvestrant)-induced Estrogen Receptor-α Degradation by the Estrogen Receptor-related Receptor-α Inverse Agonist XCT790* - Journal of Biological Chemistry
Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor α Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase | PLOS ONE
Estrogen Receptor Pathway | Progestogen Rectieptor Signaling
Estrogen receptor signaling as a target for novel breast cancer therapeutics - ScienceDirect
Dual-mechanism estrogen receptor inhibitors | PNAS
Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. - Abstract - Europe PMC
A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling
Cross-talk between nuclear receptors and nuclear factor κB | Oncogene
A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling
Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways in: Journal of Molecular Endocrinology Volume 41 Issue 5 (2008)
Dual-mechanism estrogen receptor inhibitors | PNAS
Crossroads of Estrogen Receptor and NF-κB Signaling | Science's STKE
IJMS | Free Full-Text | Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers | HTML
Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF‑κB pathway (Review)
IJMS | Free Full-Text | The Role of ERα36 in Development and Tumor Malignancy | HTML
The NF-KB pathway and endocrine therapy resistance in breast cancer in: Endocrine-Related Cancer Volume 26 Issue 6 (2019)
Impact of Apparent Antagonism of Estrogen Receptor β by Fulvestrant on Anticancer Activity of 2-Methoxyestradiol | Anticancer Research
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer | Breast Cancer Research | Full Text
Dual-mechanism estrogen receptor inhibitors | PNAS
